Phase 2 study to evaluate an oral weekly combination regimen of lenacapavir and islatravir

Back to the "HIV and Co-Infections News" list

Gilead and Merck initiate Phase 2 study evaluating an oral weekly combination regimen of investigational lenacapavir and investigational islatravir for HIV-1 treatment in virologically suppressed adults

  • HIV Treatment
October 26, 2021
Tags:

This clinical study is the first from Merck and Gilead’s collaboration to develop potential long-acting HIV treatment options

Read the full press release here.

 

Source : Merck

Related HIV and Co-Infections News

See all related HIV and Co-Infections News

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.